Medical studies use various methods for assessing agreement among different raters or measurement methods. Many of these coefficients have limitations, and among them the paradoxes of kappa are the best known. To achieve a higher accuracy and reliability, we propose an alternative statistic method based on AC1, known as CEA, which adjusts the chance agreement. We explored the influences of the prevalence rate and chance agreement probability on the total agreement and compared the accuracy and stability of kappa, AC1 and CEA coefficient through simulations and real data analysis. The proposed method offers a stable and reliable option for assessing agreement of binary data.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6765663 | PMC |
| http://dx.doi.org/10.3969/j.issn.1673-4254.2018.04.14 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a Deep Learning Denoising Algorithm for Dose Reduction in Whole-Body Photon-Counting CT Imaging: A Cadaveric Study.
Acad Radiol
January 2025
Department of Radiology, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076 Tuebingen, Germany (R.D., J.M.B., B.S., J.M., S.G., P.K., S.W., J.H., K.N., S.A., A.B.).
Rationale And Objectives: Photon Counting CT (PCCT) offers advanced imaging capabilities with potential for substantial radiation dose reduction; however, achieving this without compromising image quality remains a challenge due to increased noise at lower doses. This study aims to evaluate the effectiveness of a deep learning (DL)-based denoising algorithm in maintaining diagnostic image quality in whole-body PCCT imaging at reduced radiation levels, using real intraindividual cadaveric scans.
Materials And Methods: Twenty-four cadaveric human bodies underwent whole-body CT scans on a PCCT scanner (NAEOTOM Alpha, Siemens Healthineers) at four different dose levels (100%, 50%, 25%, and 10% mAs).
Reliability of various Antimicrobial Susceptibility Testing Methods for Piperacillin/tazobactam in challenging Escherichia coli isolates.
J Glob Antimicrob Resist
January 2025
Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address:
Piperacillin/tazobactam antimicrobial susceptibility testing (AST) against Enterobacterales can be challenging. The aim of this study was to assess the reproducibility of various automated (Vitek®2) and non-automated AST methods (broth microdilution (BMD), minimum inhibitory concentration (MIC) test strip, and disk diffusion) for piperacillin/tazobactam in 'challenging' E. coli isolates.
View Article and Find Full Text PDFAnalytical Validation of the Labcorp Plasma Complete Test, a Cell-free DNA Comprehensive Genomic Profiling Tool for Precision Oncology.
J Mol Diagn
January 2025
Labcorp Oncology (PGDx), Baltimore, MD 21224.
To help guide treatment decisions and clinical trial matching, tumor genomic profiling is an essential precision oncology tool. Liquid biopsy, a complementary approach to tissue testing, can assess tumor-specific DNA alterations circulating in the blood. Labcorp Plasma Complete is a next-generation sequencing, cell-free DNA comprehensive genomic profiling test that identifies clinically relevant somatic variants across 521 genes in advanced and metastatic solid cancers.
View Article and Find Full Text PDFPsychosocial impact associated with a multicancer early detection test (PATHFINDER): a prospective, multicentre, cohort study.
Lancet Oncol
January 2025
Health Systems and Population Health, University of Washington, Seattle, WA, USA. Electronic address:
Background: PATHFINDER was a prospective cohort study of multicancer early detection (MCED) testing in an outpatient ambulatory population. The aim of this study is to report the patient-reported outcomes (PROs) collected as secondary and exploratory measures in the PATHFINDER study.
Methods: PATHFINDER is a prospective, multicentre, cohort study that enrolled existing healthy ambulatory outpatients at seven health networks in the USA, including hospitals, academic medical centres, and integrated health systems.
Evaluation of a next generation sequencing assay for Hepatitis B antiviral drug resistance on the oxford nanopore system.
J Clin Virol
January 2025
Division of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:
Background: Next-generation sequencing (NGS) for Hepatitis B virus (HBV) antiviral resistance (AVR) testing is a highly sensitive diagnostic method, able to detect low-level mutant subpopulations. Our clinical virology laboratory previously transitioned from DNA hybridization (INNO-LiPA) to NGS, initially with the GS Junior System and subsequently the MiSeq. The Oxford Nanopore Technology (ONT) sequencing system was evaluated for HBV resistance testing, with regards to sequencing accuracy and turn-around time.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!